Antifibrogenic role of the cannabinoid receptor CB2 in the liver

B. JULIEN ; P. GRENARD ; F. TEIXEIRA-CLERC ; J. TRAN VAN NHIEU ; L. LI ; KARSAK M. ; A. ZIMMER ; A. MALLAT ; S. LOTERSZTAJN | 2005
Périodique

ENGLISH : BACKGROUND & AIMS: Hepatic myofibroblasts are central for the development of liver fibrosis associated with chronic liver diseases, and blocking their accumulation may prevent fibrogenesis. Cannabinoids are the active components of m[...]

Plus d'info

Ajouter à la sélection

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

S. STEFFENS ; N. R. VEILLARD ; C. ARNAUD ; PELLI G. ; F. BURGER ; C. STAUB ; A. ZIMMER ; FROSSARD J. L. ; MACH F. | 2005
Dans Nature (Vol.434, n°7034, 7 April 2005) Article : Périodique

Atherosclerosis is a chronic inflammatory disease, and is the primary cause of heart disease and stroke in Western countries. Derivatives of cannabinoids such as delta-9-tetrahydrocannabinol (THC) modulate immune functions and therefore have pot[...]

Plus d'info

Ajouter à la sélection